Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 2/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.36 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL724779 | 0.79 | PDE4A (0.51) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL10081725 | 0.79 | PDE4A (0.51) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL678301 | 0.72 | ALDH1A1 (0.49) | KMT2AMEN1ALDH1A1KDM4EALOX15 | |
| SCHEMBL12473954 | 0.71 | ALOX15 (0.50) | KMT2AMEN1ALDH1A1KDM4EALOX15 | |
| SCHEMBL10081724 | 0.67 | ALOX15 (0.59) | KMT2AMEN1ALDH1A1KDM4EALOX15 | |
| SCHEMBL1302136 | 0.66 | ALOX15 (0.62) | KMT2AMEN1ALDH1A1KDM4EALOX15 | |
| SCHEMBL16002382 | 0.66 | ALOX15 (0.62) | KMT2AMEN1ALDH1A1KDM4EALOX15 | |
| SCHEMBL27825750 | 0.66 | MEN1 (0.58) | KMT2AMEN1ALDH1A1MAPK1PDE4A | |
| SCHEMBL19919386 | 0.64 | ALOX15 (0.62) | KMT2AMEN1ALDH1A1KDM4EALOX15 | |
| SCHEMBL207377 | 0.64 | ALOX15 (0.59) | KMT2AMEN1ALDH1A1KDM4EALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016800-A1 | METHODS OF TREATING NEUROFIBROMATOSIS WITH PERILLYL ALCOHOL | UNIVERSITY OF SOUTHERN CALIFORNIA | 2024-01-18 | — | — | US | claimed |
| US-20230405125-A1 | TREATMENT OF RECURRENT GIOBLASTOMA WITH PERILLYL ALCOHOL | Neonc Technologies, Inc. | 2023-12-21 | — | — | US | claimed |
| US-20220054481-A1 | METHODS OF TREATING NEUROFIBROMATOSIS WITH PERILLYL ALCOHOL | UNIVERSITY OF SOUTHERN CALIFORNIA | 2022-02-24 | — | — | US | claimed |
| US-11147809-B2 | Methods of treating neurofibromatosis with perillyl alcohol | Neonc Technologies, Inc. (US) | 2021-10-19 | — | — | US | claimed |
| US-11077104-B2 | Pharmaceutical compositions comprising POH derivatives | Neonc Technologies, Inc. (US) | 2021-08-03 | — | — | US | claimed |
| US-11013804-B2 | Pharmaceutical compositions comprising POH derivatives | NeOncTechnologies, Inc. (US) | 2021-05-25 | — | — | US | claimed |
| US-20200078462-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | UNIVERSITY OF SOUTHERN CALIFORNIA | 2020-03-12 | — | — | US | claimed |
| US-20190167669-A1 | METHODS OF TREATING NEUROFIBROMATOSIS WITH PERILLYL ALCOHOL | UNIVERSITY OF SOUTHERN CALIFORNIA | 2019-06-06 | — | — | US | claimed |
| EP-3244930-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | Neonc Technologies Inc. (US) | 2017-11-22 | — | — | EP | claimed |
| US-20170297985-A1 | METHODS OF TREATING NEUROFIBROMATOSIS WITH PERILLYL ALCOHOL | NEONC TECH INC (US) | 2017-10-19 | — | — | US | claimed |
| US-20170128578-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | NEONC TECHNOLOGIES INC. | 2017-05-11 | — | — | US | claimed |
| US-9499461-B2 | Pharmaceutical compositions comprising POH derivatives | Neonc Technologies, Inc. (US) | 2016-11-22 | — | — | US | claimed |
| EP-2609064-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DERIVATIVES OF PERILLYL ALCOHOL | NEONC TECHNOLOGIES INC (US) | 2016-09-28 | — | — | EP | claimed |
| WO-2016115147-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | NEONC TECHNOLOGIES INC. (US) | 2016-07-21 | — | — | WO | claimed |
| US-20160038600-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | NATIONAL INSTITUTES OF HEALTH | 2016-02-11 | — | — | US | claimed |
| EP-2898883-A1 | Pharmaceutical compositions comprising perillyl alcohol carbamates | Neonc Technologies Inc. (US) | 2015-07-29 | — | — | EP | claimed |
| US-20130210877-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | NEONC TECHNOLOGIES INC. (US) | 2013-08-15 | — | — | US | claimed |
| EP-2609064-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | Neonc Technologies Inc. (US) | 2013-07-03 | — | — | EP | claimed |
| WO-2012027693-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | NEONC TECHNOLOGIES INC. (US) | 2012-03-01 | — | — | WO | claimed |
| US-20240197891-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2024-06-20 | — | — | US | disclosed |
| EP-4323070-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2024-02-21 | — | — | EP | disclosed |
| US-20240016800-A1 | METHODS OF TREATING NEUROFIBROMATOSIS WITH PERILLYL ALCOHOL | UNIVERSITY OF SOUTHERN CALIFORNIA | 2024-01-18 | — | — | US | disclosed |
| US-20230405125-A1 | TREATMENT OF RECURRENT GIOBLASTOMA WITH PERILLYL ALCOHOL | Neonc Technologies, Inc. | 2023-12-21 | — | — | US | disclosed |
| US-11786521-B2 | Methods of treating neurofibromatosis with perillyl alcohol | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2023-10-17 | — | — | US | disclosed |
| EP-4243794-A1 | TREATMENT OF RECURRENT GIOBLASTOMA WITH PERILLYL ALCOHOL | Neonc Technologies, Inc. (US) | 2023-09-20 | — | — | EP | disclosed |
| US-20230145207-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES AND METHODS OF USE | UNIVERSITY OF SOUTHERN CALIFORNIA | 2023-05-11 | — | — | US | disclosed |
| US-11559508-B2 | Pharmaceutical compositions comprising POH derivatives and methods of use | Neonc Technologies, Inc. (US) | 2023-01-24 | — | — | US | disclosed |
| WO-2022104041-A1 | TREATMENT OF RECURRENT GIOBLASTOMA WITH PERILLYL ALCOHOL | Neonc Technologies, Inc. (US) | 2022-05-19 | — | — | WO | disclosed |
| US-20220133712-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | UNIVERSITY OF SOUTHERN CALIFORNIA | 2022-05-05 | — | — | US | disclosed |
| US-20220054481-A1 | METHODS OF TREATING NEUROFIBROMATOSIS WITH PERILLYL ALCOHOL | UNIVERSITY OF SOUTHERN CALIFORNIA | 2022-02-24 | — | — | US | disclosed |
| US-11147809-B2 | Methods of treating neurofibromatosis with perillyl alcohol | Neonc Technologies, Inc. (US) | 2021-10-19 | — | — | US | disclosed |
| US-20210283127-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | UNIVERSITY OF SOUTHERN CALIFORNIA | 2021-09-16 | — | — | US | disclosed |
| US-20210244820-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | UNIVERSITY OF SOUTHERN CALIFORNIA | 2021-08-12 | — | — | US | disclosed |
| US-11077104-B2 | Pharmaceutical compositions comprising POH derivatives | Neonc Technologies, Inc. (US) | 2021-08-03 | — | — | US | disclosed |
| US-11013804-B2 | Pharmaceutical compositions comprising POH derivatives | NeOncTechnologies, Inc. (US) | 2021-05-25 | — | — | US | disclosed |
| EP-3806838-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | Neonc Technologies, Inc. (US) | 2021-04-21 | — | — | EP | disclosed |
| WO-2021061752-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | Neonc Technologies, Inc. (US) | 2021-04-01 | — | — | WO | disclosed |
| US-20200237697-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES AND METHODS OF USE | UNIVERSITY OF SOUTHERN CALIFORNIA | 2020-07-30 | — | — | US | disclosed |
| EP-3685835-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | Neonc Technologies, Inc. (US) | 2020-07-29 | — | — | EP | disclosed |
| US-20200230132-A1 | METHODS OF TREATING CANCER USING COMPOSITIONS COMPRISING PERILLYL ALCOHOL DERIVATIVE | NATIONAL INSTITUTES OF HEALTH | 2020-07-23 | — | — | US | disclosed |
| US-20200078355-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | Neonc Technologies, Inc. | 2020-03-12 | — | — | US | disclosed |
| US-20200078462-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | UNIVERSITY OF SOUTHERN CALIFORNIA | 2020-03-12 | — | — | US | disclosed |
| US-20190275031-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | UNIVERSITY OF SOUTHERN CALIFORNIA | 2019-09-12 | — | — | US | disclosed |
| US-20190167669-A1 | METHODS OF TREATING NEUROFIBROMATOSIS WITH PERILLYL ALCOHOL | UNIVERSITY OF SOUTHERN CALIFORNIA | 2019-06-06 | — | — | US | disclosed |
| US-20190054082-A1 | METHODS OF TREATING CANCER USING COMPOSITIONS COMPRISING PERILLYL ALCOHOL DERIVATIVE | NATIONAL INSTITUTES OF HEALTH | 2019-02-21 | — | — | US | disclosed |
| WO-2019014420-A1 | COMPOSITIONS AND METHODS OF DECREASING MEDICATION ERRORS | AZHC, LLC (US) | 2019-01-17 | — | — | WO | disclosed |
| US-10092562-B2 | Pharmaceutical compositions comprising POH derivatives | Neonc Technologies, Inc. (US) | 2018-10-09 | — | — | US | disclosed |
| US-9913838-B2 | Methods of treating cancer using compositions comprising perillyl alcohol derivative | Neonc Technologies, Inc. (US) | 2018-03-13 | — | — | US | disclosed |
| US-20170369408-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | NEONC TECHNOLOGIES INC | 2017-12-28 | — | — | US | disclosed |
| EP-3244930-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | Neonc Technologies Inc. (US) | 2017-11-22 | — | — | EP | disclosed |
| EP-3244930-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | Neonc Technologies Inc. (US) | 2017-11-22 | — | — | EP | disclosed |
| US-20170297985-A1 | METHODS OF TREATING NEUROFIBROMATOSIS WITH PERILLYL ALCOHOL | NEONC TECH INC (US) | 2017-10-19 | — | — | US | disclosed |
| EP-3173080-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | Neonc Technologies Inc. (US) | 2017-05-31 | — | — | EP | disclosed |
| US-9663428-B2 | Pharmaceutical compositions comprising POH derivatives | NEONC TECHNOLOGIES INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20170128578-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | NEONC TECHNOLOGIES INC. | 2017-05-11 | — | — | US | disclosed |
| US-20170119758-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | UNIVERSITY OF SOUTHERN CALIFORNIA | 2017-05-04 | — | — | US | disclosed |
| US-9580372-B2 | Pharmaceutical compositions comprising POH derivatives | NEONC TECHNOLOGIES INC. (US) | 2017-02-28 | — | — | US | disclosed |
| EP-2898883-B1 | Pharmaceutical compositions comprising perillyl alcohol carbamates | NEONC TECHNOLOGIES INC (US) | 2016-11-23 | — | — | EP | disclosed |
| US-9499461-B2 | Pharmaceutical compositions comprising POH derivatives | Neonc Technologies, Inc. (US) | 2016-11-22 | — | — | US | disclosed |
| EP-2883543-B1 | Pharmaceutical compositions comprising perillyl alcohol carbamates | NEONC TECHNOLOGIES INC (US) | 2016-11-16 | — | — | EP | disclosed |
| EP-2609064-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DERIVATIVES OF PERILLYL ALCOHOL | NEONC TECHNOLOGIES INC (US) | 2016-09-28 | — | — | EP | disclosed |
| US-20160243114-A1 | METHODS OF TREATING CANCER USING COMPOSITIONS COMPRISING PERILLYL ALCOHOL DERIVATIVE | UNIVERSITY OF SOUTHERN CALIFORNIA | 2016-08-25 | — | — | US | disclosed |
| WO-2016115147-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | NEONC TECHNOLOGIES INC. (US) | 2016-07-21 | — | — | WO | disclosed |
| WO-2016115147-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | NEONC TECHNOLOGIES INC. (US) | 2016-07-21 | — | — | WO | disclosed |
| US-20160038600-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | NATIONAL INSTITUTES OF HEALTH | 2016-02-11 | — | — | US | disclosed |
| US-20160039731-A1 | Pharmaceutical Compositions Comprising Deuterium-Enriched Perillyl Alcohol, Iso-Perillyl Alcohol and Derivatives Thereof | NEONC TECHNOLOGIES INC | 2016-02-11 | — | — | US | disclosed |
| EP-2898883-A1 | Pharmaceutical compositions comprising perillyl alcohol carbamates | Neonc Technologies Inc. (US) | 2015-07-29 | — | — | EP | disclosed |
| EP-2883543-A1 | Pharmaceutical compositions comprising perillyl alcohol carbamates | Neonc Technologies Inc. (US) | 2015-06-17 | — | — | EP | disclosed |
| WO-2015054333-A1 | METHODS OF TREATING CANCER USING COMPOSITIONS COMPRISING PERILLYL ALCOHOL DERIVATIVE | Neonc Technologies, Inc. (US) | 2015-04-16 | — | — | WO | disclosed |
| US-8916545-B2 | Pharmaceutical compositions comprising POH derivatives | NEONC TECHNOLOGIES INC. (US) | 2014-12-23 | — | — | US | disclosed |
| US-20140364471-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | UNIVERSITY OF SOUTHERN CALIFORNIA | 2014-12-11 | — | — | US | disclosed |
| US-20140364472-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | UNIVERSITY OF SOUTHERN CALIFORNIA | 2014-12-11 | — | — | US | disclosed |
| US-20130210877-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | NEONC TECHNOLOGIES INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130203828-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | NEO ONCOLOGY INC. (US) | 2013-08-08 | — | — | US | disclosed |
| EP-2609064-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | Neonc Technologies Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| WO-2012027693-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | NEONC TECHNOLOGIES INC. (US) | 2012-03-01 | — | — | WO | disclosed |
| WO-2012027693-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | NEONC TECHNOLOGIES INC. (US) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (32 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220133712-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | PLIN3, PLIN5, DOHH | KMT2A 2466/4885MEN1 1164/4885ALDH1A1 610/4885 |
| US-20130203828-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | PLIN3, PLIN5, DOHH | KMT2A 2466/4885MEN1 1164/4885ALDH1A1 610/4885 |
| US-20230145207-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES AND METHODS OF USE | ACADVL, CPT1A, ADH5 | KMT2A 1939/4885MEN1 1893/4885ALDH1A1 272/4885 |
| US-20200230132-A1 | METHODS OF TREATING CANCER USING COMPOSITIONS COMPRISING PERILLYL ALCOHOL DERIVATIVE | POLH, PLIN3, POLE3 | KMT2A 2066/4885MEN1 3807/4885ALDH1A1 895/4885 |
| US-20190054082-A1 | METHODS OF TREATING CANCER USING COMPOSITIONS COMPRISING PERILLYL ALCOHOL DERIVATIVE | PLIN3, CHAT, PLIN5 | KMT2A 548/4885MEN1 756/4885ALDH1A1 324/4885 |
| US-20160038600-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | PDE3A, PDE3B, PDE5A | KMT2A 990/4885MEN1 1452/4885ALDH1A1 205/4885 |
| US-20190275031-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | PLIN3, PLIN5, DOHH | KMT2A 2466/4885MEN1 1164/4885ALDH1A1 610/4885 |
| US-20240197891-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | PLIN3, PLIN5, PLIN1 | KMT2A 4089/4885MEN1 4696/4885ALDH1A1 102/4885 |
| US-20170128578-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | PLIN3, PLIN5, DOHH | KMT2A 2466/4885MEN1 1164/4885ALDH1A1 610/4885 |
| US-20220054481-A1 | METHODS OF TREATING NEUROFIBROMATOSIS WITH PERILLYL ALCOHOL | PMP22, CHAT, REL | KMT2A 471/4885MEN1 585/4885ALDH1A1 46/4885 |
| US-20190167669-A1 | METHODS OF TREATING NEUROFIBROMATOSIS WITH PERILLYL ALCOHOL | PMP22, CHAT, REL | KMT2A 471/4885MEN1 585/4885ALDH1A1 46/4885 |
| US-11147809-B2 | Methods of treating neurofibromatosis with perillyl alcohol | PMP22, CHAT, REL | KMT2A 471/4885MEN1 585/4885ALDH1A1 46/4885 |
| US-20170369408-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | PLIN3, PLIN5, DOHH | KMT2A 2466/4885MEN1 1164/4885ALDH1A1 610/4885 |
| US-20170297985-A1 | METHODS OF TREATING NEUROFIBROMATOSIS WITH PERILLYL ALCOHOL | PMP22, REL, CHAT | KMT2A 534/4885MEN1 610/4885ALDH1A1 48/4885 |
| US-20160243114-A1 | METHODS OF TREATING CANCER USING COMPOSITIONS COMPRISING PERILLYL ALCOHOL DERIVATIVE | POLH, TOP2A, PLIN3 | KMT2A 2237/4885MEN1 3775/4885ALDH1A1 721/4885 |
| US-20200078355-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | PLIN3, PLIN5, DOHH | KMT2A 2466/4885MEN1 1164/4885ALDH1A1 610/4885 |
| US-20160039731-A1 | Pharmaceutical Compositions Comprising Deuterium-Enriched Perillyl Alcohol, Iso-Perillyl Alcohol and Derivatives Thereof | ADH1C, ADH1A, ADH5 | KMT2A 2276/4885MEN1 2165/4885ALDH1A1 323/4885 |
| US-11077104-B2 | Pharmaceutical compositions comprising POH derivatives | PLIN3, PLIN5, DOHH | KMT2A 2466/4885MEN1 1164/4885ALDH1A1 610/4885 |
| US-20240016800-A1 | METHODS OF TREATING NEUROFIBROMATOSIS WITH PERILLYL ALCOHOL | PMP22, CHAT, REL | KMT2A 471/4885MEN1 585/4885ALDH1A1 46/4885 |
| US-20210283127-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | PLIN3, PLIN5, DOHH | KMT2A 2466/4885MEN1 1164/4885ALDH1A1 610/4885 |
| US-11786521-B2 | Methods of treating neurofibromatosis with perillyl alcohol | PMP22, CHAT, REL | KMT2A 471/4885MEN1 585/4885ALDH1A1 46/4885 |
| US-20170119758-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | PLIN3, PLIN5, DOHH | KMT2A 2380/4885MEN1 1258/4885ALDH1A1 627/4885 |
| US-20140364472-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | PLIN3, PLIN5, DOHH | KMT2A 2466/4885MEN1 1164/4885ALDH1A1 610/4885 |
| US-10092562-B2 | Pharmaceutical compositions comprising POH derivatives | PLIN3, PLIN5, DOHH | KMT2A 2466/4885MEN1 1164/4885ALDH1A1 610/4885 |
| US-20140364471-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | PLIN3, PLIN5, DOHH | KMT2A 2380/4885MEN1 1258/4885ALDH1A1 627/4885 |
| US-20210244820-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | PLIN3, PLIN5, NR1H3 | KMT2A 3869/4885MEN1 4803/4885ALDH1A1 265/4885 |
| US-11559508-B2 | Pharmaceutical compositions comprising POH derivatives and methods of use | ACADVL, CPT1A, ADH5 | KMT2A 1939/4885MEN1 1893/4885ALDH1A1 272/4885 |
| US-20230405125-A1 | TREATMENT OF RECURRENT GIOBLASTOMA WITH PERILLYL ALCOHOL | IDH3A, IDH1, IDH3B | KMT2A 482/4885MEN1 852/4885ALDH1A1 162/4885 |
| US-20200237697-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES AND METHODS OF USE | ACADVL, CPT1A, ADH5 | KMT2A 1939/4885MEN1 1893/4885ALDH1A1 272/4885 |
| US-20200078462-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | PDE3A, PDE3B, PDE5A | KMT2A 990/4885MEN1 1452/4885ALDH1A1 205/4885 |
| US-11013804-B2 | Pharmaceutical compositions comprising POH derivatives | PDE3A, PDE3B, PDE5A | KMT2A 990/4885MEN1 1452/4885ALDH1A1 205/4885 |
| US-20130210877-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | PLIN3, PLIN5, DOHH | KMT2A 2466/4885MEN1 1164/4885ALDH1A1 610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.